Media stories about Assembly Biosciences (NASDAQ:ASMB) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Assembly Biosciences earned a news sentiment score of 0.22 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.264793299629 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Several equities analysts have commented on the stock. Chardan Capital assumed coverage on shares of Assembly Biosciences in a research report on Tuesday, May 30th. They set a “buy” rating and a $35.00 target price on the stock. BidaskClub raised shares of Assembly Biosciences from a “strong sell” rating to a “sell” rating in a research report on Thursday.

Assembly Biosciences (NASDAQ:ASMB) traded up 1.27% during trading on Monday, reaching $23.13. 33,219 shares of the company’s stock traded hands. The firm’s market cap is $401.21 million. Assembly Biosciences has a 12 month low of $5.41 and a 12 month high of $28.24. The firm has a 50 day moving average price of $21.60 and a 200-day moving average price of $22.50.

TRADEMARK VIOLATION WARNING: “Assembly Biosciences (NASDAQ:ASMB) Receiving Somewhat Positive Media Coverage, Analysis Shows” was reported by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at

About Assembly Biosciences

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Insider Buying and Selling by Quarter for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with's FREE daily email newsletter.